Skip to main content
NovartisIn development

New long-term Rhapsido® (remibrutinib) Phase III data show sustained efficacy through week 52 in chronic inducible urticaria (CIndU)

Source: Autobound Signal API · 77 signals tracked for Novartis · updated

Get Novartis' live signals in Claude or ChatGPT, or by API

AskWhat changed at Novartis this week? Use Autobound signals for novartis.com.

What happened

Novartis announced 52-week results from the Phase III RemIND program evaluating Rhapsido (remibrutinib) in chronic inducible urticaria.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Basel, November 12, 2026 – Novartis today announced 52-week results from the Phase III RemIND program evaluating Rhapsido ® (remibrutinib) in chronic inducible urticaria (CIndU). In the long-term analysis from the RemIND study, Rhapsido 25 mg twice daily showed early and sustained efficacy through Week 52 in patients across the three most prevalent CIndU subtypes: symptomatic dermographism (SD), cold urticaria (ColdU) and cholinergic urticaria (CholU). 1 The data will be presented as a late-breaking abstract at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting 2026.

globenewswire.com/news-release/2026/11/12/3402010/0/en/new-long-term-...Read the full source

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Product
Rhapsido
Location
Basel, Basel-Stadt, Switzerland

The full record

From the Signal API record

Topics and mentions

Product tags

  • medical

Extraction

Confidence
95%
Detected
Nov 12, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for Novartis and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Novartis this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/1de588ed-3492-3302-c574-6a898152ce5f returns this record as JSON. POST /v1/companies/enrich returns every signal for novartis.com.

{
  "signal_id": "1de588ed-3492-3302-c574-6a898152ce5f",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-11-12T16:57:00+00:00",
  "company": {
    "name": "Novartis",
    "domain": "novartis.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/11/12/3402010/0/en/new-long-term-rhapsido-remibrutinib-phase-iii-data-show-sustained-efficacy-through-week-52-in-chronic-inducible-urticaria-cindu.html",
    "title": "New long-term Rhapsido® (remibrutinib) Phase III data show sustained efficacy through week 52 in chronic inducible urticaria (CIndU)",
    "excerpt": "Basel, November 12, 2026 – Novartis today announced 52-week results from the Phase III RemIND program evaluating Rhapsido ® (remibrutinib) in chronic inducible urticaria (CIndU). In the long-term analysis from the RemIND study, Rhapsido 25 mg twice daily showed early and sustained efficacy through Week 52 in patients across the three most prevalent CIndU subtypes: symptomatic dermographism (SD), cold urticaria (ColdU) and cholinergic urticaria (CholU). 1 The data will be presented as a late-breaking abstract at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting 2026.",
    "product": "Rhapsido",
    "summary": "Novartis announced 52-week results from the Phase III RemIND program evaluating Rhapsido (remibrutinib) in chronic inducible urticaria.",
    "location": "Basel, Switzerland",
    "planning": false,
    "confidence": 0.95,
    "product_data": {
      "name": "Rhapsido",
      "full_text": "Rhapsido ® (remibrutinib)",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-11-12T16:57:00Z",
    "location_data": [
      {
        "city": "Basel",
        "state": "Basel-Stadt",
        "region": "Western Europe",
        "country": "Switzerland",
        "continent": "Europe",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "Novartis today announced 52-week results from the Phase III RemIND program evaluating Rhapsido ® (remibrutinib) in chronic inducible urticaria (CIndU)."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.